Literature DB >> 25212275

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

X Cabagnols1, J P Defour2, V Ugo3, J C Ianotto4, P Mossuz5, J Mondet5, F Girodon6, J H Alexandre7, O Mansier8, J F Viallard9, E Lippert8, A Murati10, M J Mozziconacci10, P Saussoy11, M C Vekemans12, L Knoops13, F Pasquier1, V Ribrag1, E Solary1, I Plo1, S N Constantinescu14, N Casadevall15, W Vainchenker1, C Marzac16, O Bluteau1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25212275     DOI: 10.1038/leu.2014.270

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

Review 2.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

3.  Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.

Authors:  Ayalew Tefferi; Emnet A Wassie; Paola Guglielmelli; Naseema Gangat; Alem A Belachew; Terra L Lasho; Christy Finke; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani; Alexandra P Wolanskyj; Margherita Maffioli; Rosario Casalone; Annalisa Pacilli; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

4.  Looking for CALR mutations in familial myeloproliferative neoplasms.

Authors:  M Maffioli; A Genoni; D Caramazza; B Mora; A Bussini; M Merli; T Giorgino; R Casalone; F Passamonti
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Authors:  Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

8.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis.

Authors:  J Chi; K A Nicolaou; V Nicolaidou; L Koumas; A Mitsidou; C Pierides; M Manoloukos; K Barbouti; F Melanthiou; C Prokopiou; G S Vassiliou; P Costeas
Journal:  Leukemia       Date:  2013-12-24       Impact factor: 11.528

View more
  32 in total

Review 1.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

3.  Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Authors:  Luca Malcovati; Elisa Rumi; Mario Cazzola
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

Review 4.  JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.

Authors:  Michele Ciboddo; Ann Mullally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Mutant calreticulin in myeloproliferative neoplasms.

Authors:  Joan How; Gabriela S Hobbs; Ann Mullally
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

6.  The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

Authors:  M O Holmström; C H Riley; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

7.  Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.

Authors:  Kyohei Misawa; Hajime Yasuda; Marito Araki; Tomonori Ochiai; Soji Morishita; Shuichi Shirane; Yoko Edahiro; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2018-02-20       Impact factor: 2.490

8.  Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.

Authors:  Katte Rao Toppaldoddi; Maira da Costa Cacemiro; Olivier Bluteau; Barbara Panneau-Schmaltz; Amélie Pioch; Delphine Muller; Jean-Luc Villeval; Hana Raslova; Stefan N Constantinescu; Isabelle Plo; William Vainchenker; Caroline Marty
Journal:  Oncogene       Date:  2018-10-19       Impact factor: 9.867

Review 9.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.

Authors:  Xavier Cahu; Stefan N Constantinescu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 10.  Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.

Authors:  Ross L Levine; Elodie Pronier; Tiffany R Merlinsky
Journal:  Clin Cancer Res       Date:  2019-01-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.